Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...